Date published: 2026-7-9

1-800-457-3801

SCBT Portrait Logo
Seach Input

ZAR1 CRISPR/Cas9 KO Plasmid (h): sc-406501

0.0(0)
Write a reviewAsk a question

Datasheets
  • Target species: human
  • 20 µg of transfection-ready, purified plasmid DNA; Suitable for up to 20 transfections
  • ZAR1 CRISPR/Cas9 Knockout (KO) Plasmid (h) is a pool of plasmids, each encoding Cas9 nuclease and a target-specific 20 nt guide RNA (gRNA) designed for maximum knockout efficiency using sequences derived from the GeCKO v2 library
  • gRNA sequences direct Cas9 to induce site-specific double-strand breaks (DSBs) in the ZAR1 genomic locus, resulting in gene knockout through non-homologous end joining (NHEJ)
  • The puromycin resistance and RFP genes are flanked by LoxP sites, enabling removal of selection markers via Cre recombinase (Cre Vector: sc-418923) after establishing stable knockout cell lines
    Gene Editing Promo Banner

    Ordering Information

    Product NameCatalog #UNITPriceQtyFAVORITES

    ZAR1 CRISPR/Cas9 KO Plasmid (h)

    sc-406501
    20 µg
    $397.00

    Overview

    ZAR1 (zygote arrest 1) encodes an RNA-binding protein best characterized for roles in early embryogenesis, where it supports oocyte-to-zygote transition and post-transcriptional control of maternal mRNAs. In human cells, ZAR1 is linked to regulation of mRNA stability/translation and cytoplasmic ribonucleoprotein granule dynamics, processes that shape cell-cycle progression and developmental competence. Altered expression or dysregulation of maternal-effect and germline-associated RNA regulatory factors has been associated with infertility phenotypes and developmental failure in model systems, making ZAR1 relevant to studies of reproductive biology and early developmental pathways. As a maternally enriched factor, ZAR1 also provides a tractable node for investigating how RNA regulatory networks intersect with stress responses and differentiation programs.

    ZAR1 CRISPR/Cas9 KO Plasmid (h) is a pool of plasmids designed for targeted disruption of the ZAR1 gene in human cell lines. Each plasmid co-expresses a unique single guide RNA (sgRNA) targeting a distinct site within the ZAR1 together with the Streptococcus pyogenes Cas9 nuclease. The plasmids also encode GFP, allowing fluorescent identification and enrichment of successfully transfected cells by fluorescence microscopy or flow cytometry.

    The multi-guide design increases the likelihood of generating insertions or deletions (indels) that disrupt the ZAR1 open reading frame following Cas9-mediated double-strand break formation. DNA breaks introduced by the CRISPR/Cas9 system are repaired through endogenous non-homologous end joining (NHEJ) pathways, frequently resulting in frameshift mutations that abolish ZAR1 protein expression.

    This CRISPR knockout system enables efficient generation of ZAR1-deficient cell models for investigation of ZAR1 signaling, functional genomics studies, cancer biology research, and evaluation of therapeutic responses in human cell lines.

    Key Features

    • sgRNAs targeting ZAR1 exon(s) critical for ZAR1 function
    • Co-expression of SpCas9 and sgRNA from a single plasmid for simplified delivery
    • GFP reporter for identification of transfected cells
    • Pool of plasmids targeting multiple ZAR1 genomic sites to improve knockout efficiency
    • Compatible with delivery by transfection

    Design Variants

    CRISPRs +/- HDRs

    • gRNAs encoded by ZAR1 CRISPR/Cas9 KO Plasmid (h) and ZAR1 CRISPR/Cas9 KO Plasmid (h2) target distinct sites within the ZAR1 locus. One or both targeting designs may be available. See Related Products for availability.
    • HDR donor constructs encoded by ZAR1 HDR Plasmid (h) and ZAR1 HDR Plasmid (h2) contain a puromycin resistance cassette and an RFP reporter flanked by ZAR1 homology arms to support homology-directed repair at defined ZAR1 target sites corresponding to the CRISPR/Cas9 KO designs. HDR donor availability may vary. See Related Products for availability.

    For Research Use Only. Not Intended for Diagnostic or Therapeutic Use.